Thomas Martin Kuendig - 01 Oct 2025 Form 4 Insider Report for XBiotech Inc. (XBIT)

Reporting relationship: Director
Issuer ticker: XBIT
Reported as of: 01 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Nov 2025, 09:53:42 UTC
Prior SEC filing: 30 Sep 2025
Source filing: View source filing
Reporting owner signature: Thomas Kuendig

Key filing fact

Thomas Martin Kuendig filed Form 4 for XBiotech Inc. (XBIT) on 12 Nov 2025.

Key facts

This page summarizes Thomas Martin Kuendig's Form 4 filing for XBiotech Inc. (XBIT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Nov 2025, 09:53.

Change

Previous filing in this sequence was filed on 30 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002088590 Primary reporting owner

Kuendig Thomas Martin

Relationship: Director
Address: ALPENSTRASSE 23, 8803 RUESCHLIKON, KANTON OF ZUERICH, RUESCHLIKON, SWITZERLAND
Signature: Thomas Kuendig
Signature date: 12 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XBIT transaction Derivative

Director Stock Option

Award

Transaction value: $0
Shares: +79,115
Change %
Price: $0.000000
Shares after: 79,115
Date: 01 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 79,115
Exercise price: $2.64

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

On October 1, 2025 (the Grant Date) the reporting person was granted nonstatutory stock options (the Options) under the Company's 2025 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions at four month and ten month from the Grant Date with an expiry of ten years from the Grant Date.T